IP Verse

Engineered Nucleic Acids And Methods Of Use Thereof - EP3431485

The patent EP3431485 was granted to Moderna on Sep 4, 2024. The application was originally filed on Oct 3, 2011 under application number EP18179157A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3431485

MODERNA
Application Number
EP18179157A
Filing Date
Oct 3, 2011
Status
Patent Maintained As Amended
Aug 2, 2024
Grant Date
Sep 4, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GLPSep 30, 2021PETRAZADMISSIBLE
GLAXOSMITHKLINESep 30, 2021RACINEWITHDRAWN

Patent Citations (44) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20020436050
DESCRIPTIONUS20030740645
DESCRIPTIONUS4270537
DESCRIPTIONUS4596556
DESCRIPTIONUS4790824
DESCRIPTIONUS4886499
DESCRIPTIONUS4940460
DESCRIPTIONUS4941880
DESCRIPTIONUS5015235
DESCRIPTIONUS5064413
DESCRIPTIONUS5141496
DESCRIPTIONUS5190521
DESCRIPTIONUS5312335
DESCRIPTIONUS5328483
DESCRIPTIONUS5334144
DESCRIPTIONUS5339163
DESCRIPTIONUS5383851
DESCRIPTIONUS5417662
DESCRIPTIONUS5466220
DESCRIPTIONUS5480381
DESCRIPTIONUS5503627
DESCRIPTIONUS5520639
DESCRIPTIONUS5527288
DESCRIPTIONUS5569189
DESCRIPTIONUS5599302
DESCRIPTIONUS5649912
DESCRIPTIONUS5704911
DESCRIPTIONUS5893397
DESCRIPTIONUS5993412
DESCRIPTIONWO9713537
DESCRIPTIONWO9737705
DESCRIPTIONWO9934850
OPPOSITIONWO2007024708
OPPOSITIONWO2008052770
OPPOSITIONWO2008083949
OPPOSITIONWO2012045082
OPPOSITIONWO2012170930
OPPOSITIONWO9822510
OPPOSITIONWO9914346
SEARCHWO2007024708
SEARCHWO2008052770
SEARCHWO2008083949
SEARCHWO9822510
SEARCHWO9914346

Non-Patent Literature (NPL) Citations (69) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ALBRECHT, Immunotherapy, (20100000), vol. 2, no. 6, pages 795 - 8
DESCRIPTION- ARENZANA-SEISDEDOS F et al., Nature, (19961003), vol. 383, no. 6599, page 400
DESCRIPTION- ATSCHUL, S. F. et al., J. Molec. Biol., (19900000), vol. 215, page 403
DESCRIPTION- BUHLER et al., Cell, (20060000), vol. 125, pages 873 - 886
DESCRIPTION- CARILLO et al., SIAM J. Applied Math., (19880000), vol. 48, page 1073
DESCRIPTION- CARILLO, H.; LIPMAN, D., SIAM J Applied Math., (19880000), vol. 48, page 1073
DESCRIPTION- DEVEREUX, J. et al., Nucleic Acids Research, (19840000), vol. 12, no. 1, page 387
DESCRIPTION- KARIKO K et al., Immunity, (20050000), vol. 23, pages 165 - 175
DESCRIPTION- KARIKO K et al., Mol Ther, (20080000), vol. 16, pages 1833 - 1840
DESCRIPTION- KIKLY K; LIU L; NA S; SEDGWICK JD, Curr. Opin. Immunol., (20060000), vol. 18, no. 6, pages 670 - 675
DESCRIPTION- MEYERS; MILLER, CABIOS, (19890000), vol. 4, pages 11 - 17
DESCRIPTION- MOTAMEDI et al., Cell, (20040000), vol. 119, pages 789 - 802
DESCRIPTION- MUSUNURU K et al., "From noncoding variant to phenotype via SORT1 at the lpl3 cholesterol locus", Nature, (20100000), vol. 466, pages 714 - 721
DESCRIPTION- "Oligonucleotide synthesis: methods and applications", Methods in Molecular Biology, Humana Press, (20050000), vol. 288
DESCRIPTION- ROZENSKI, J; CRAIN, P; MCCLOSKEY, J, "The RNA Modification Database: 1999 update", Nucl Acids Res, (19990000), vol. 27, pages 196 - 197
OPPOSITION- Bakker, J.M. Bleeker, W.K. Parren, P.W.H.I., "Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity", Molecular Therapy, Elsevier Inc., US, US, (20040901), vol. 10, no. 3, doi:10.1016/j.ymthe.2004.06.865, ISSN 1525-0016, pages 411 - 416
OPPOSITION- FELIPE DE P, "POLYCISTRONIC VIRAL VECTORS", Current Gene Therapy, Bentham Science Publishers Ltd., NL, NL, (20020901), vol. 02, no. 03, doi:10.2174/1566523023347742, ISSN 1566-5232, pages 355 - 378
OPPOSITION- GRAY ES et al., "Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual", J Virol, (20110525), vol. 85, no. 15, pages 7719 - 29
OPPOSITION- HEIDENREICH, O. et al., "High activity and stability of hammerhead Cited in D2 ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates", Journal of Biological Chemistry, (19940121), vol. 269, no. 3, pages 2131 - 2138
OPPOSITION- HEIDENREICH, O. et al., "High activity and stability of hammerhead Cited in D2 ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates", Journal of Biological Chemistry, (19940121), vol. 269, no. 3, pages 2131 - 2138, XP002096819
OPPOSITION- Ishii Ken J; Akira Shizuo, "TLR ignores methylated RNA?", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL, (20050801), vol. 23, no. 2, doi:10.1016/j.immuni.2005.08.003, ISSN 1074-7613, pages 111 - 113
OPPOSITION- JIANGDONG L, "Recombinant IgG Expression in Mammalian Cells", PhD Dissertation, Technischen Universität Carolo-Wilhelmina, (20060000), URL: https://d-nb.info/981284973/34
OPPOSITION- JIANGDONG L, "Recombinant IgG Expression in Mammalian Cells", PhD Dissertation, Technischen Universität Carolo-Wilhelmina, (20060000), URL: https://d-nb.info/981284973/34, XP055190605
OPPOSITION- Kariko Katalin; Weissman Drew, "Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development.", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, GB, (20070101), vol. 10, no. 5, ISSN 1367-6733, pages 523 - 532
OPPOSITION- Kariko Katalin; Weissman Drew, "Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development.", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, GB, (20070101), vol. 10, no. 5, ISSN 1367-6733, pages 523 - 532, XP009154595
OPPOSITION- KAUFMAN R.J., ET AL., "IMPROVED VECTORS FOR STABLE EXPRESSION OF FOREIGN GENES IN MAMMALIAN CELLS BY USE OF THE UNTRANSLATED LEADER SEQUENCE FROM EMC VIRUS.", Nucleic Acids Research, Oxford University Press, GB, GB, (19910101), vol. 19., no. 16., ISSN 0305-1048, pages 4485 - 4490.
OPPOSITION- KAUFMAN R.J., ET AL., "IMPROVED VECTORS FOR STABLE EXPRESSION OF FOREIGN GENES IN MAMMALIAN CELLS BY USE OF THE UNTRANSLATED LEADER SEQUENCE FROM EMC VIRUS.", Nucleic Acids Research, Oxford University Press, GB, GB, (19910101), vol. 19., no. 16., ISSN 0305-1048, pages 4485 - 4490., XP002008547
OPPOSITION- Kim & Eberwine. Mamahan cell transfection, the present and the future Anal Bioanal Chem (2010) 397- 3173-3178
OPPOSITION- Li, J. Menzel, C. Meier, D. Zhang, C. Dubel, S. Jostock, T., "A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies", Journal of Immunological Methods, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM., NL, NL, (20070103), vol. 318, no. 1-2, doi:10.1016/j.jim.2006.10.010, ISSN 0022-1759, pages 113 - 124
OPPOSITION- MIZUGUCHI H ET AL, "IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector.", Molecular Therapy, Elsevier Inc., US, US, (20000401), vol. 1, no. 4, doi:10.1006/mthe.2000.0050, ISSN 1525-0016, pages 376 - 382
OPPOSITION- Pardi et al. Nat Common. 2017, 8-14630
OPPOSITION- Perez Norma et al, "Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation", GENETIC VACCINES AND THERAPY, BIOMED CENTRAL, LONDON, GB, GB, (20040323), vol. 2, no. 1, doi:10.1186/1479-0556-2-2, ISSN 1479-0556, page 2
OPPOSITION- Post-published data filed during the prosecution of the parent application
OPPOSITION- PRUD'HOMME GéRALD J, ET AL, "Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases.", Current Gene Therapy, Bentham Science Publishers Ltd., NL, NL, (20060401), vol. 6, no. 2, doi:10.2174/156652306776359504, ISSN 1566-5232, pages 243 - 273
OPPOSITION- Rybakova et al. Mol Ther. 2019, 27(8): 1415-1423
OPPOSITION- SCALLAN, DC et al., "Phenotypic correction of a mouse model of haemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII", Blood, (20031201), vol. 102, no. 12, pages 3919 - 3926
OPPOSITION- SCHLATTER S et al., "On the Optimal Ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells", Biotechnol Prog, (20050000), vol. 21, doi:10.1021/BP049780W, pages 122 - 133
OPPOSITION- Subba Rao Nallagatla, Rebecca Toroney, Philip C. Bevilacqua, "A brilliant disguise for self RNA: 5’-end and internal modifications of primary transcripts suppress elements of innate immunity", RNA Biology, Landes Bioscience, (20080701), vol. 5, no. 3, doi:10.4161/rna.5.3.6839, ISSN 15476286, pages 140 - 144
OPPOSITION- Thran et al EMBO Mol Med 2017, 9(10). 1434-1447
OPPOSITION- TJELLE TE et al., "Monoclonal antibodies produced by muscle after plasmid injection and electroporation", Mol Ther., (20040300), vol. 9, no. 3, doi:10.1016/j.ymthe.2003.12.007, pages 328 - 36
OPPOSITION- Yamamoto A. et al, "Current prospects for mRNA gene delivery", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL, (20090301), vol. 71, no. 3, doi:10.1016/j.ejpb.2008.09.016, ISSN 0939-6411, pages 484 - 489
OPPOSITION- Yuri Motorin, Et Al., "5-methylcytosine in RNA: detection, enzymatic formation and biological functions", Nucleic Acids Research, Oxford University Press, GB, GB, (20100301), vol. 38, no. 5, doi:10.1093/nar/gkp1117, ISSN 0305-1048, pages 1415 - 1430
OPPOSITION- MIZUGUCHI H ET AL, "IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector.", Molecular Therapy, Elsevier Inc., US, US, (20000401), vol. 1, no. 4, doi:10.1006/mthe.2000.0050, ISSN 1525-0016, pages 376 - 382, XP002213078
OPPOSITION- Yamamoto A. et al, "Current prospects for mRNA gene delivery", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL, (20090301), vol. 71, no. 3, doi:10.1016/j.ejpb.2008.09.016, ISSN 0939-6411, pages 484 - 489, XP025992169
OPPOSITION- Kariko K, Buckstein M, Ni H, Weissman D, "Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL, (20050801), vol. 23, no. 2, doi:10.1016/J.IMMUNI.2005.06.008, ISSN 1074-7613, pages 165 - 175, XP002634064
OPPOSITION- KARIKÓ K et al., "Suppression of RNA Recognition by Toll-like Receptor: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA", Immunity, (20050801), vol. 23, no. 2, pages 165 - 175, XP008104240
OPPOSITION- Ishii Ken J; Akira Shizuo, "TLR ignores methylated RNA?", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL, (20050801), vol. 23, no. 2, doi:10.1016/j.immuni.2005.08.003, ISSN 1074-7613, pages 111 - 113, XP007912341
OPPOSITION- Li, J. Menzel, C. Meier, D. Zhang, C. Dubel, S. Jostock, T., "A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies", Journal of Immunological Methods, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM., NL, NL, (20070103), vol. 318, no. 1-2, doi:10.1016/j.jim.2006.10.010, ISSN 0022-1759, pages 113 - 124, XP005820142
OPPOSITION- TJELLE TE et al., "Monoclonal antibodies produced by muscle after plasmid injection and electroporation", Mol Ther., (20040300), vol. 9, no. 3, doi:10.1016/j.ymthe.2003.12.007, pages 328 - 36, XP055415724
OPPOSITION- Torunn Elisabeth Tjelle et al, "Monoclonal Antibodies Produced by Muscle after Plasmid Injection and Electroporation", Molecular Therapy, Elsevier Inc., US, US, (20040301), vol. 9, no. 3, doi:10.1016/j.ymthe.2003.12.007, ISSN 1525-0016, pages 328 - 336, XP055415724
OPPOSITION- Bakker, J.M. Bleeker, W.K. Parren, P.W.H.I., "Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity", Molecular Therapy, Elsevier Inc., US, US, (20040901), vol. 10, no. 3, doi:10.1016/j.ymthe.2004.06.865, ISSN 1525-0016, pages 411 - 416, XP004536751
OPPOSITION- MCLEAN G R, ET AL, "Human and murine immunoglobulin expression vector cassettes", MOLECULAR IMMUNOLOGY, PERGAMON, GB, GB, (20001001), vol. 37, no. 14, doi:10.1016/S0161-5890(00)00101-2, ISSN 0161-5890, pages 837 - 845, XP002562175
OPPOSITION- MCLEAN GR et al., "Human and murine immunoglobulin expression vector cassettes", proceedings Mol Immunol, (20000000), vol. 37, doi:10.1016/S0161-5890(00)00101-2, pages 837 - 845, XP002562175
OPPOSITION- SCHLATTER S, ET AL, "On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells", Biotechnology Progress, American Chemical Society, (20050101), vol. 21, no. 1, doi:10.1021/BP049780W, ISSN 8756-7938, pages 122 - 133, XP008123445
OPPOSITION- SCHLATTER S et al., "On the Optimal Ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells", Biotechnol Prog, (20050000), vol. 21, doi:10.1021/BP049780W, pages 122 - 133, XP008123445
OPPOSITION- KARIKo KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.", Molecular Therapy, Nature Publishing Group, GB, GB, (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0024, pages 1833 - 1840, XP002598556
OPPOSITION- KARIKÓ K et al., "Incorporation of Pseudouridine Into proceedings mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability", Mol Ther, (20080916), vol. 16, no. 11, pages 1833 - 1840, XP002598556
OPPOSITION- Yuri Motorin, Et Al., "5-methylcytosine in RNA: detection, enzymatic formation and biological functions", Nucleic Acids Research, Oxford University Press, GB, GB, (20100301), vol. 38, no. 5, doi:10.1093/nar/gkp1117, ISSN 0305-1048, pages 1415 - 1430, XP055681117
OPPOSITION- ANDERSON BR et al., "Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation", Nucleic Acids Res., (20100510), vol. 38, no. 17, doi:10.1093/nar/gkq347, pages 5884 - 92, XP055041208
OPPOSITION- B. R. Anderson et al, "Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation", Nucleic Acids Research, Information Retrieval Ltd., (20100901), vol. 38, no. 17, doi:10.1093/nar/gkq347, ISSN 03051048, pages 5884 - 5892, XP055041208
OPPOSITION- GRAY ES et al., "Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual", J Virol, (20110525), vol. 85, no. 15, pages 7719 - 29, XP055850011
OPPOSITION- SCALLAN, DC et al., "Phenotypic correction of a mouse model of haemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII", Blood, (20031201), vol. 102, no. 12, pages 3919 - 3926, XP055850008
OPPOSITION- Perez Norma et al, "Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation", GENETIC VACCINES AND THERAPY, BIOMED CENTRAL, LONDON, GB, GB, (20040323), vol. 2, no. 1, doi:10.1186/1479-0556-2-2, ISSN 1479-0556, page 2, XP021009747
OPPOSITION- FELIPE DE P, "POLYCISTRONIC VIRAL VECTORS", Current Gene Therapy, Bentham Science Publishers Ltd., NL, NL, (20020901), vol. 02, no. 03, doi:10.2174/1566523023347742, ISSN 1566-5232, pages 355 - 378, XP001205951
OPPOSITION- PRUD'HOMME GéRALD J, ET AL, "Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases.", Current Gene Therapy, Bentham Science Publishers Ltd., NL, NL, (20060401), vol. 6, no. 2, doi:10.2174/156652306776359504, ISSN 1566-5232, pages 243 - 273, XP002634890
OPPOSITION- Subba Rao Nallagatla, Rebecca Toroney, Philip C. Bevilacqua, "A brilliant disguise for self RNA: 5’-end and internal modifications of primary transcripts suppress elements of innate immunity", RNA Biology, Landes Bioscience, (20080701), vol. 5, no. 3, doi:10.4161/rna.5.3.6839, ISSN 15476286, pages 140 - 144, XP055112032
SEARCH- MCLEAN G R ET AL, "Human and murine immunoglobulin expression vector cassettes", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 37, no. 14, ISSN 0161-5890, (20001001), pages 837 - 845, (20001001), XP027300186 [Y] 1-6 * the whole document *
SEARCH- KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 11, doi:10.1038/MT.2008.200, ISSN 1525-0024, (20081101), pages 1833 - 1840, (20080916), XP002598556 [Y] 1-6 * the whole document *
SEARCH- B. R. ANDERSON ET AL, "Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation", NUCLEIC ACIDS RESEARCH, (20100901), vol. 38, no. 17, doi:10.1093/nar/gkq347, ISSN 0305-1048, pages 5884 - 5892, XP055041208 [Y] 1-6 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents